Foresee Pharmaceuticals Co Ltd (6576) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has a cash flow conversion efficiency ratio of -0.162x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.53 Million ≈ $-4.96 Million USD) by net assets (NT$971.84 Million ≈ $30.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Foresee Pharmaceuticals Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Foresee Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Foresee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Foresee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Tractor Company Limited
F:FTP
|
0.097x |
|
Kretam Holdings Bhd
KLSE:1996
|
0.152x |
|
Djurslands Bank
CO:DJUR
|
0.002x |
|
WPG (Shanghai) Smart Water Public Co. Ltd
SHG:603956
|
0.020x |
|
GDI Integrated
TO:GDI
|
0.066x |
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
N/A |
|
Samji Electronics Co. Ltd
KQ:037460
|
-0.371x |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
0.019x |
Annual Cash Flow Conversion Efficiency for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Foresee Pharmaceuticals Co Ltd (6576) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.60 Billion ≈ $50.38 Million |
NT$-1.17 Billion ≈ $-36.98 Million |
-0.734x | -2.93% |
| 2023-12-31 | NT$1.24 Billion ≈ $39.21 Million |
NT$-887.55 Million ≈ $-27.96 Million |
-0.713x | -178.45% |
| 2022-12-31 | NT$910.58 Million ≈ $28.69 Million |
NT$-233.22 Million ≈ $-7.35 Million |
-0.256x | -58.50% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.59 Million |
NT$-213.33 Million ≈ $-6.72 Million |
-0.162x | +56.19% |
| 2020-12-31 | NT$1.83 Billion ≈ $57.63 Million |
NT$-674.80 Million ≈ $-21.26 Million |
-0.369x | +26.20% |
| 2019-12-31 | NT$895.86 Million ≈ $28.22 Million |
NT$-447.82 Million ≈ $-14.11 Million |
-0.500x | +46.10% |
| 2018-12-31 | NT$498.62 Million ≈ $15.71 Million |
NT$-462.43 Million ≈ $-14.57 Million |
-0.927x | -15.89% |
| 2017-12-31 | NT$603.66 Million ≈ $19.02 Million |
NT$-483.10 Million ≈ $-15.22 Million |
-0.800x | -- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more